UltraSight joins MedTech Innovator’s 2026 accelerator cohort

By AI, Created 12:51 PM UTC, June 03, 2026, /AGP/ – UltraSight has been selected for MedTech Innovator’s 2026 Accelerator Cohort and the inaugural MTI Index after ranking among the top 4% of 1,835 global applicants. The move gives the AI-guided cardiac imaging company access to MedTech Innovator’s summit, investor showcases and commercialization network as it pushes to expand access to cardiac ultrasound.

Why it matters: - UltraSight’s selection puts the AI-guided cardiac imaging company inside MedTech Innovator’s largest accelerator network for medical device, digital health and diagnostic startups. - The recognition can help UltraSight build investor relationships, clinical credibility and commercial traction as it works to expand cardiac ultrasound access. - The inaugural MTI Index adds a new benchmark that investors, health systems, strategic partners and media can use to track emerging medtech companies.

What happened: - UltraSight was selected for MedTech Innovator’s 2026 Accelerator Cohort and named to the inaugural MTI Index. - The company was chosen from 1,835 global applicants. - MedTech Innovator picked 65 companies, putting UltraSight in the top 4% of applicants. - UltraSight will attend the invitation-only Innovator Summit in San Francisco from June 2-4. - UltraSight will also present at investor showcase events alongside Wilson Sonsini’s Medical Device & Digital Health Conference.

The details: - MedTech Innovator’s four-month accelerator is built to support early- and growth-stage companies. - The program offers mentorship, commercialization guidance, strategic introductions, investor engagement and ecosystem access. - The selection process included reviews from investors, clinicians, healthcare systems and industry experts. - The MTI Index is designed as a centralized framework for identifying medtech companies showing clinical, operational and commercial progress. - The Annual Cohort Index will be released each year with the cohort announcement. - Specialty Indexes by therapeutic category will roll out on a rolling basis. - MTI plans periodic updates to show movement, category trends and inflection points. - UltraSight develops AI-guided imaging software that helps trained healthcare professionals acquire diagnostic-quality cardiac ultrasound images using real-time guidance and quality assessment. - UltraSight’s technology targets hospital, outpatient and point-of-care settings. - UltraSight’s Echosystem combines structured training, real-time AI guidance and advanced analytics. - The Echosystem is designed to let non-cardiac sonographer providers perform focused echocardiography exams under qualified physician oversight. - UltraSight says the platform supports focused and limited transthoracic echocardiography workflows that generally align with existing U.S. Medicare reimbursement pathways. - UltraSight’s software has FDA 510(k) clearance to assist medical professionals in performing cardiac ultrasound scans. - The company’s website is www.ultrasight.com. - The MTI Index can be viewed at the 2026 MTI Index.

Between the lines: - The selection suggests MedTech Innovator sees UltraSight as one of the more promising companies in a crowded cardiac imaging and medtech market. - Inclusion in the MTI Index may increase visibility with investors and health systems looking for companies with near-term clinical and commercial momentum. - UltraSight’s focus on point-of-care and non-cardiac users points to a broader push to make echocardiography easier to deploy outside traditional cardiology workflows.

What’s next: - UltraSight will use the accelerator to pursue mentorship, introductions and investor exposure. - The company will present to investors during the June summit window in San Francisco. - MTI will continue expanding the index with yearly cohort updates and category-specific releases. - UltraSight is expected to keep advancing its AI-guided imaging platform for healthcare providers and broader cardiac imaging access.

The bottom line: - UltraSight now has a high-profile accelerator platform and a new industry benchmark to help accelerate its push into cardiac ultrasound workflows.